摘要
目的:探讨可溶性B7-H4(soluble B7-H4,sB7-H4)在早期胃癌中的诊断价值。方法:应用酶联免疫吸附试验(ELISA)夹心法检测80例早期胃癌患者与50例正常人血清sB7-H4水平,用化学发光法检测血清CEA、CA19-9水平,利用受试者工作特性曲线(ROC),比较分析sB7-H4作为早期胃癌血清标志物的诊断价值。结果:早期胃癌患者血清sB7-H4水平(47.61±13.57)ng/ml明显高于正常人(30.62±8.65)ng/ml,差异有统计学意义(P<0.01)。sB7-H4在早期胃癌诊断中的灵敏度(81.25%)和准确性(78.46%)均高于CEA及CA19-9,特异性(74%)低于CEA及A199。结论:sB7-H4在早期胃癌诊断中具有良好的临床应用前景,联合检测sB7-H4、CEA和CA19-9可提高胃癌的诊断率。
Objective:To discuss the diagnosis value of soluble B7-H4(sB7-H4) in early gastric cancer.Methods:Using ELISA sandwich method,the serum level of soluble B7-H4 was detected in 80 cases of early gastric cancer patients and 50 cases of normal people,Chemiluminescence method was adopted to determine the serum CEA and CA19-9 levels,then analyzed the diagnosis value of sB7-H4 in early gastric cancer with ROC(Receiver Operating Characteristic).Results:The serum level of soluble B7-H4 in early gastric cancer patients [(47.61±13.57)ng/ml]was significantly higher than that in normal people[(30.62±8.65)ng/ml],there was significant difference within them(P0.01).The sensitivity(81.25%) and accuracy(78.46%) of sB7-H4 in early gastric cancer was higher than CEA and CA19-9,but the specificity(74%) was lower than CEA and CA19-9.Conclusion:Soluble B7-H4 have good prospects in clinical application on diagnosing early gastric cancer,detecting the serum levels of sB7-H4,together with CEA and CA19-9 can raise the positive rate of early gastric cancer.
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2012年第8期745-747,共3页
Chinese Journal of Immunology
基金
深圳市科技计划项目(No.200803231)
深圳市宝安区科技计划项目(No.2008174)